We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker-Based Blood Test Does Not Completely Replace CT Scan for Diagnosis of Elderly Concussion Patients

By LabMedica International staff writers
Posted on 14 Jan 2020
A recent study confirmed that the GFAP/UCH-L1 blood test could predict with 100% accuracy which elderly concussion patients did not have brain tissue damage and were not in need of a CT scan.

More than 50 million people worldwide sustain a traumatic brain injury (TBI) annually. More...
Detection of intracranial injuries relies on head CT, which is an overused and resource intensive method. Blood-based brain biomarkers hold the potential to predict absence of intracranial injury and thus reduce unnecessary head CT scanning. The [U.S.] Food and Drug Administration has approved use of a blood test that identifies head injury patients who have brain tissue damage that needs to be assessed via CT scan. However, the performance of this test, which determines levels of the proteins serum glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal esterase L1 (UCH-L1) has not been characterized in elderly patients.

In this regard, investigators at the University of Maryland School of Medicine (Baltimore, USA) sought to characterize any difference in the predictive performance of the GFAP/UCH-L1 biomarkers-based test between younger patients, (less than 65 years old) and older patients (more than 65 years old).

For this work, the investigators retrospectively analyzed data from the Prospective Clinical Evaluation of Biomarkers of Traumatic Brain Injury (ALERT-TBI) study. In this study, 1,959 adult patients with a concussion underwent both a CT scan and blood test for brain tissue damage within 12 hours of their injury. Elderly mild TBI patients constituted 25.7% of the patient cohort (504/1959).

Results revealed that the GFAP/UCH-L1 blood test predicted which elderly concussion patients did not have brain tissue damage and did not need a CT scan with 100% accuracy. However, the test did not accurately identify elderly patients who had suffered brain tissue damage, suggesting that the test should only be used as a triage tool, not as a replacement for CT scans.

“This post-hoc analysis of the ALERT-TBI study further validates the utility of the [mild traumatic brain injury] serum assay as a rule-out test across the spectrum of adult ages, based on equivalent sensitivity and negative predictive value,” said senior author Dr. Robert H. Christenson, professor of pathology and medical and research technology at the University of Maryland School of Medicine. “However, the identified differences in specificity and serum GFAP/UCH-L1 values in elderly [traumatic brain injury] patients limits use as a rule-in test, and highlights age-specific characteristics that must be considered in the use of the predictive markers in elderly [mild traumatic brain injury] patients.”

The study was published in the December 30, 2019, online edition of The Journal of Applied Laboratory Medicine.

Related Links:
University of Maryland School of Medicine


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.